Plus   Neg

Stock Alert: Biohaven Pharmaceutical Jumps 10% On Nurtec Revenues

Shares of Biohaven Pharmaceutical Holding Co. Ltd. (BHVN) are currently gaining nearly 10% after the company reported revenues of Nurtec ODT.

BHVN is currently trading at $72.30, up $6.52 or 9.91%, on the Nasdaq.

Biohaven announced preliminary product revenue of $43.8 million fro Nurtec ODT, rimegepant, for the first quarter. Total prescriptions of Nurtec ODT from product launch to date as of March 31, 2021 were over 500,000, with over 30,000 unique prescribers.

CEO Vlad Coric said, "Despite the typical first quarter insurance dynamics associated with new year prior authorizations/deductibles and the winter surge of COVID-19 affecting prescription volumes, NURTEC ODT continues to grow quarter over quarter in both prescription volume and net revenue."

For comments and feedback contact: editorial@rttnews.com

Follow RTT